Europe has found ways to make value-based care work, but the US market is very different, which means there are different factors in the United States that can work to encourage high-value care, according to Jennifer Graff, PharmD, vice president of comparative effectiveness research at the National Pharmaceutical Council.
Europe has found ways to make value-based care work, but the US market is very different, which means there are different factors in the United States that can work to encourage high-value care, according to Jennifer Graff, PharmD, vice president of comparative effectiveness research at the National Pharmaceutical Council.
Transcript (slightly modified)
What can we learn from models of approval and reimbursement decision making of specialty drugs in other countries, particularly throughout Europe?
The United States is quite a different market than Europe; we see this in a really fragmented market. Let me give you an example; in Europe, if you pay for a treatment that may cure a disease or slow the progression, the patient stays within that single-payer health system. So, the payer that paid for that medication at one point in time, will also receive the benefits of that treatment, either in lower healthcare costs, or better healthcare for that patient several years down the road. In the US that patient has likely moved on to a second or third health plan, so they aren’t reaping those benefits. So, while we can learn many things from Europe, the United States is a complex system.
What can we do in the United States? I think there are 3 things. First, for patients, we need to make sure we are incentivizing patients to get the treatments that work best for them. There are things that we can do to make sure that patients—who just by bad luck, bad genes, or have tried and failed other treatment alternatives and now need more costly therapies—that they aren’t hit with a double whammy of higher copay or coinsurance, as well as poor health. We can do things to try to ensure that patients are paying for treatments and not penalized financially for their genes or bad luck.
The second is encouraging providers. We have a very sick fragmented healthcare system; so if you incentivize a provider in one way to encourage high value care then the hospital or the payer may have different incentives, so it gets very complex. We need to align these incentives from the provider, to the health system, to the payer to encourage high value care rather than low value care and therefore free up dollars.
The third element that we need to consider is, how does our payment landscape work? We have legal, regulatory, and information technology (IT) barriers that are really challenging the opportunities to develop new and innovative payment landscapes. So, we can hopefully address these by multi-stakeholder collaboratives, public-private partnerships, and others to try to ensure that those legal issues such as anti-kickback statute of limitations, regulatory issues such as Medicaid Best Price, or even IT issues to provide payment for the indication that the patient is receiving the treatment for—that those are all resolved so we can incentivize high care value and treatments.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Kathy Oubre on Strategies to Mitigate Challenges When Adopting New Payment Models
February 23rd 2024While adopting new payment models can come with challenges, there are strategies that can help oncology practices optimize their approaches, said Kathy Oubre, MS, CEO of Pontchartrain Cancer Center.
Read More
Getting to Know Dr Shauna Downs, Public Health Nutritionist
February 23rd 2024Shauna Downs, PhD, MS, is an associate professor in the Department of Health Behavior, Society, and Policy at the Rutgers School of Public Health. A former figure skater, her research now focuses on interventions to promote healthy and sustainable food choices and exploring how our changing climate, food systems, diet, and nutrition are inextricably linked.
Read More